Drug intelligence / Profile preview

RS-013

Development stage: Preclinical
Lead developer: Related Sciences

Overview

RS-013 is a preclinical-stage drug candidate being developed by Related Sciences for the treatment of autoimmune and inflammatory diseases. Discovered and prioritized using Related Sciences' proprietary Facets machine learning platform, the program is currently in the late discovery phase of preclinical development. Specific details regarding the drug's molecular target, therapeutic modality, and exact mechanism of action remain undisclosed.

Beyond the preview

Go deeper on RS-013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS-013.

Explore the full profile